What Is DHEA-S (Female)? Normal vs Optimal Range Explained

The lab range of 35–430 µg/dL spans from a postmenopausal woman with depleted adrenal reserves to a teenager at peak adrenal output—a nearly twelve-fold range that renders a single "normal" result almost meaningless without age context. DHEA-S declines approximately 2 percent per year after age 25, so a 35-year-old woman with DHEA-S of 80 µg/dL is technically "normal" by lab standards but is functioning at adrenal levels typical of a 70-year-old. The CTD maps over 1,400 compound interactions with DHEA metabolism genes, reflecting the hormone's extensive downstream conversion pathways into testosterone, estrogen, and numerous neurosteroids. The optimal 150–350 µg/dL band represents robust adrenal reserve where DHEA-S can adequately contribute to sex hormone production, immune function, and stress resilience. DHEA-S is the most stable adrenal androgen to measure because, unlike cortisol, it does not fluctuate with the circadian cycle or acute stress—making it a reliable single-draw assessment of adrenal androgen capacity at any time of day.

PubMed indexes over 11,000 clinical publications on DHEA-S, with its clinical utility split between two contexts: evaluating androgen excess (PCOS workup) and assessing adrenal reserve (fatigue and stress-related complaints). Approximately 20–30 percent of women with PCOS have elevated DHEA-S above 400 µg/dL, indicating that the excess androgens driving their symptoms come from the adrenal glands rather than the ovaries—a distinction that influences treatment choices. The cortisol-to-DHEA-S ratio is emerging as a more informative measure than either hormone alone: high cortisol with low DHEA-S reflects chronic stress depleting adrenal reserves through the "pregnenolone steal" phenomenon, where the shared precursor pregnenolone is preferentially shunted toward cortisol production at the expense of DHEA-S. Women with elevated cortisol-to-DHEA-S ratios above their age-adjusted threshold consistently report higher fatigue severity and lower subjective stress resilience on validated quality-of-life assessments.

Very high DHEA-S—above 700 µg/dL in women—warrants imaging of the adrenal glands because adrenal tumors (adenomas and carcinomas) can autonomously produce DHEA-S at levels far exceeding normal physiological output. On the treatment side, DHEA supplementation (typically 25–50 mg daily) has been used in women with diminished ovarian reserve undergoing IVF, with some fertility clinics reporting improved egg quality and pregnancy rates—though the evidence remains mixed and individual response varies substantially. For women with documented low DHEA-S and symptoms of adrenal depletion, a monitored supplementation trial with repeat testing at six to eight weeks is a reasonable clinical approach, provided testosterone levels are also tracked to avoid unwanted androgenic side effects such as acne, hirsutism, and voice deepening that can occur with excessive androgen conversion.